Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

poll finding that one in eight adult Americans has taken a Glucagon-like peptide-1 (GLP-1), the technical name for ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update NeuroBo Becomes MetaVia On November 18, 2024, NeuroBo Pharmaceuticals ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

Medically reviewed by Peter Weiss, MD Ozempic is the brand name of a medication called semaglutide, a glucagon-like peptide-1 ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

Nearly half of participants in a weight loss program who initiated an antiobesity medication and who consumed alcohol ...

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...

Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...